Abstract
The transmission heterogeneity of an epidemic is associated with a complex mixture of host, pathogen and environmental factors. And it may indicate superspreading events to reduce the efficiency of population-level control measures and to sustain the epidemic over a larger scale and a longer duration. Methods have been proposed to identify significant transmission heterogeneity in historic epidemics based on several data sources, such as contact history, viral genomes and spatial information, which is sophisticated and may not be available, and more importantly ignore the temporal trend of transmission heterogeneity. Here we attempted to establish a convenient method to estimate real-time heterogeneity over an epidemic. Within the branching process framework, we introduced an instant-individualheterogenous infectiousness model to jointly characterized the variation in infectiousness both between individuals and among different times. With this model, we could simultaneously estimate the transmission heterogeneity and the reproduction number from incidence time series. We validated the model with both simulated data and five historic epidemics. Our estimates of the overall and real-time heterogeneities of the five epidemics were consistent with those presented in the literature. Additionally, our model is robust to the ubiquitous bias of under-reporting and misspecification of serial interval. By analyzing the recent data from South Africa, we found evidences that the Omicron might be of more significant transmission heterogeneity than the Delta. Our model based on incidence data was proved to be reliable in estimating the real-time transmission heterogeneity.
Author summary The transmission of many infectious diseases is usually heterogeneous in time and space. Such transmission heterogeneity may indicate superspreading events (where some infected individuals transmit to disproportionately more susceptible than others), reduce the efficiency of the population-level control measures, and sustain the epidemic over a larger scale and a longer duration. Classical methods of monitoring epidemic spread centered on the reproduction number which represent the average transmission potential of the epidemic at the population level, but failed to reflect the systematic variation in transmission. Several recent methods have been proposed to identify significant transmission heterogeneity in the epidemics such as Ebola, MERS, COVID-19. However, these methods are developed based on some sophisticated information such as contact history, viral genome and spatial information, of the confirmed cases, which are typically field-specific and not easy to generalize. In this study, we proposed a simple and generic method of estimating transmission heterogeneity from incidence time series, which provided consistent estimation of heterogeneity with those records with sophisticated data. It also helps in exploring the transmission heterogeneity of the newly emerging variant of Omicron. Our model enhances current understanding of epidemic dynamics, and highlight the potential importance of targeted control measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Y.J.Z and X.H.Z acknowledge support from National Natural Science 489 Foundation of China (Grant number: 82041023), the Bill & Melinda Gates Foundation 490 (Grant number: INV-016826) . T.B. is supported by The Swedish Research Council 491 (grant 2020-04744).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* yunjun.zhang{at}pku.edu.cn, azhou{at}math.pku.edu.cn
Data Availability
All data produced are available online
https://github.com/yunPKU/infer_heterogeneity_from_incidence
